Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
NATURE COMMUNICATIONS
Authors: Picco, Gabriele; Chen, Elisabeth D.; Alonso, Luz Garcia; Behan, Fiona M.; Goncalves, Emanuel; Bignell, Graham; Matchan, Angela; Fu, Beiyuan; Banerjee, Ruby; Andersonl, Elizabeth; Butler, Adam; Benes, Cyril H.; McDermott, Ultan; Dow, David; Iorio, Francesco; Stronach, Euan; Yang, Fengtang; Yusa, Kosuke; Saez-Rodriguez, Julio; Garnett, Mathew J.
Abstract
Many gene fusions are reported in tumours and for most their role remains unknown. As fusions are used for diagnostic and prognostic purposes, and are targets for treatment, it is crucial to assess their function in cancer. To systematically investigate the role of fusions in tumour cell fitness, we utilized RNA-sequencing data from 1011 human cancer cell lines to functionally link 8354 fusion events with genomic data, sensitivity to >350 anti-cancer drugs and CRISPR-Cas9 loss-of-fitness effects. Established clinically-relevant fusions were identified. Overall, detection of functional fusions was rare, including those involving cancer driver genes, suggesting that many fusions are dispensable for tumour fitness. Therapeutically actionable fusions involving RAF1, BRD4 and ROS1 were verified in new histologies. In addition, recurrent YAP1-MAML2 fusions were identified as activators of Hippo-pathway signaling in multiple cancer types. Our approach discriminates functional fusions, identifying new drivers of carcinogenesis and fusions that could have clinical implications.
Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation
BRITISH JOURNAL OF DERMATOLOGY
Authors: Bessis, D.; Miquel, J.; Bourrat, E.; Chiaverini, C.; Morice-Picard, F.; Abadie, C.; Manna, F.; Baumann, C.; Best, M.; Blanchet, P.; Bursztejn, A-C; Capri, Y.; Coubes, C.; Giuliano, F.; Guillaumont, S.; Hadj-Rabia, S.; Jacquemont, M-L; Jeandel, C.; Lacombe, D.; Mallet, S.; Mazereeuw-Hautier, J.; Molinari, N.; Pallure, V; Pernet, C.; Philip, N.; Pinson, L.; Sarda, P.; Sigaudy, S.; Vial, Y.; Willems, M.; Genevieve, D.; Verloes, A.; Cave, H.
Abstract
Background Data on dermatological manifestations of Noonan syndrome (NS) remain heterogeneous and are based on limited dermatological expertise. Objectives To describe the dermatological manifestations of NS, compare them with the literature findings, and test for dermatological phenotype-genotype correlations with or without the presence of PTPN11 mutations. Methods We performed a large 4-year, prospective, multicentric, collaborative dermatological and genetic study. Results Overall, 129 patients with NS were enrolled, including 65 patients with PTPN11-NS, 34 patients with PTPN11-NS with multiple lentigines (NSML), and 30 patients with NS who had a mutation other than PTPN11. Easy bruising was the most frequent dermatological finding in PTPN11-NS, present in 53 center dot 8% of patients. Multiple lentigines and cafe-au-lait macules (n >= 3) were present in 94% and 80% of cases of NSML linked to specific mutations of PTPN11, respectively. Atypical forms of NSML could be associated with NS with RAF1 or NRAS mutations. In univariate analysis, patients without a PTPN11 mutation showed (i) a significantly higher frequency of keratinization disorders (P = 0 center dot 001), including keratosis pilaris (P = 0 center dot 005), ulerythema ophryogenes (P = 0 center dot 0001) and palmar and/or plantar hyperkeratosis (P = 0 center dot 06, trend association), and (ii) a significantly higher frequency of scarce scalp hair (P = 0 center dot 035) and scarce or absent eyelashes (P = 0 center dot 06, trend association) than those with PTPN11 mutations. Conclusions The cutaneous phenotype of NS with a PTPN11 mutation is generally mild and nonspecific, whereas the absence of a PTPN11 mutation is associated with a high frequency of keratinization disorders and hair abnormalities.
COA
Publication 
 Antibody_1.gif)
Loading ......
